IADR Abstract Archives

Activity of Taurolidine Gels on Ex-Vivo Periodontal Biofilm

Objectives: To evaluate the activity of taurolidine (TAU) gels in comparison with a 0.2% chlorhexidine (CHX) gel on an ex-vivo subgingival biofilm.
Methods: Subgingival biofilm samples chronic from periodontitis patients were cultured for 10 d, before TAU 2% and TAU 3% gels and CHX gel were applied. Bacterial counts, biofilm quantity and biofilm activity were determined after 60 min, 24 h as well as after repeated addition of subgingival biofilm for 24 h (reformation of biofilm).
Results: Decrease of bacterial counts in biofilms was highest (up to 0.87 log10 cfu) after application of TAU 3% gel after 60 min, 24 h and reformation of biofilms. All antimicrobials reduced biofilm quantity after 24 h and after reformation of biofilms. Activity in biofilms was significantly reduced 60 min and 24 h after application of TAU gels, activity of the reformed biofilm was lower after application of any antimicrobial than in the control without exposure to antimicrobials.
Conclusions: The antimicrobial activity of taurolidine gels clearly depends on their taurolidine concentration. The TAU 3% gel seems to have equal or even superior antimicrobial activity than 0.2% chlorhexidine gel. However, activity of antimicrobials is limited on a complex established biofilm which underlines the need of a mechanical disrupture of biofilms. As an adjunctive antimicrobial TAU 3% gel might be a potential alternative to chlorhexidine gel in non-surgical periodontal therapy.
Division: IADR/AADR/CADR General Session
Meeting: 2017 IADR/AADR/CADR General Session (San Francisco, California)
Location: San Francisco, California
Year: 2017
Final Presentation ID: 4035
Abstract Category|Abstract Category(s): Periodontal Research-Therapy
Authors
  • Eick, Sigrun  ( University of Bern , Bern , Switzerland )
  • Pirracchio, Luca  ( University of Bern , Bern , Switzerland )
  • Sculean, Anton  ( University of Berne , Berne , Switzerland )
  • Support Funding Agency/Grant Number: Geistlich Pharma AG, Wolhusen, Switzerland
    Financial Interest Disclosure: NONE
    SESSION INFORMATION
    Poster Session
    Novel Approaches to Treat Periodontal Diseases
    Saturday, 03/25/2017 , 03:45PM - 05:00PM